Author:
Ai Rizi,Hammaker Deepa,Boyle David L.,Morgan Rachel,Walsh Alice M.,Fan Shicai,Firestein Gary S.,Wang Wei
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference34 articles.
1. Burmester, G. R., Feist, E. & Dörner, T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 77–88 (2014).
2. Firestein, G. S. The disease formerly known as rheumatoid arthritis. Arthritis Res. Ther. 16, 114 (2014).
3. Pincus, T. & Castrejón, I. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull. Hosp. Jt. Dis. (2013) 71, (Suppl 1): S33–S40 (2013).
4. Castrejón, I. & Pincus, T. Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin. Exp. Rheumatol. 30, S50–S55 (2012).
5. Guyot, P. et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res. Ther. 13, R204 (2011).